Related Experiment Video

Updated: May 30, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?

Paul Pharoah, Antonis Antoniou, Andrew Berchuck

    The Lancet. Oncology
    |August 3, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
    07:13

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

    Published on: March 26, 2014

    Related Experiment Videos

    Last Updated: May 30, 2026

    Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
    11:12

    Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

    Published on: August 1, 2018

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
    07:13

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

    Published on: March 26, 2014

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a superfamily...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Untargeted metabolomics of cervicovaginal fluid in patients with ovarian cancer.

    Journal of clinical and translational science·2026

    Psychosocial Stress Exposures and Advanced Disease at Ovarian Cancer Diagnosis.

    Cancer control : journal of the Moffitt Cancer Center·2026

    Characterizing the composition and diversity of the vaginal microbiome in ovarian cancer.

    Communications medicine·2026

    Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

    Gynecologic oncology·2026

    Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

    Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer.

    Nature communications·2026

    Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

    The Lancet. Oncology·2026

    Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

    The Lancet. Oncology·2026

    Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

    The Lancet. Oncology·2026

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

    The Lancet. Oncology·2026

    Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

    The Lancet. Oncology·2026

    Minimally invasive surgery without a uterine manipulator versus open radical hysterectomy for early-stage cervical cancer: A retrospective propensity-score-matched single-center cohort study.

    Gynecologic oncology·2026

    Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein-Barr virus-positive diffuse large B-cell lymphoma.

    Frontiers in immunology·2026

    Multimodality evaluation of bilateral parotid oncocytomas: A rare case report and literature review.

    Radiology case reports·2026

    Cribriform tumors of the skin: CD38 expression distinguishes from histologic mimics in a multi-institutional series.

    Virchows Archiv : an international journal of pathology·2026

    Gastric amphicrine carcinoma in the stomach: an unexpected presentation of MUTYH-associated polyposis.

    Journal of pathology and translational medicine·2026

    Limitations of evaluating risks of all cancers combined in etiological epidemiology research.

    Global epidemiology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us